BioNano Genomics Inc vs Kraft Heinz Co — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Kraft Heinz Co trades at $25.56 (market cap $29.74B). The key difference: Kraft Heinz Co is far larger — about 2253× BioNano Genomics Inc's market cap, and Kraft Heinz Co pays a 6.38% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | KHC | |
|---|---|---|
Market Cap | $13.20M | $29.74B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $28.94 |
52-Week Low | $1.09 | $21.21 |
Enterprise Value | $15.81M | $46.78B |
Dividend Yield | — | 6.38% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Kraft Heinz (KHC) trades at $25.23, up 1.53% with a bullish technical trend and strong recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.04 and P/B of 0.71, though profitability remains challenged with negative net income margins. Recent corporate restructuring aims to accelerate growth, while a 6.4% dividend yield provides income support. Cash flow trends have improved significantly from 2022's negative $2.4B to 2025's positive $1.46B.
The outlook remains cautious despite technical strength. While undervaluation and dividend yield offer appeal, persistent negative profitability and high debt levels pose significant risks. Analyst consensus is predominantly Hold with a $23.50 price target below current levels, suggesting limited near-term upside potential amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →